LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Inicio・Lista de Acciones・Roivant Sciences Ltd

Roivant Sciences Ltd

Cerrado

SectorSanidad

28.54 -2.56

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

28.18

Máximo

29.34

Métricas clave
By Trading Economics
Ingresos	-200M -314M
Ventas	428K 2M
Margen de beneficios	-15,692.896
Empleados	750
EBITDA	-132M -290M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+20.55% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	5.5B 21B
Apertura anterior	31.1
Cierre anterior	28.54

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

298 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

11 / 11.18 Soporte y Resistencia

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 may 2026, 23:10 UTC

Acciones populares

Stocks to Watch: Agilysys, XP

18 may 2026, 18:44 UTC

Principales Movimientos del Mercado

Claritev Shares Recover After Comments About DOJ

18 may 2026, 23:55 UTC

Ganancias

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 may 2026, 23:37 UTC

Charlas de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

18 may 2026, 20:25 UTC

Ganancias

Correct: XP 1Q Total Client Assets BRL1.53T

18 may 2026, 20:23 UTC

Ganancias

XP 1Q Total Client Assets BRL1.53B

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Adj EPS BRL2.49 >XP

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Rev BRL4.73B >XP

18 may 2026, 19:10 UTC

Charlas de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 may 2026, 19:00 UTC

Ganancias

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 may 2026, 18:52 UTC

Charlas de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 may 2026, 18:17 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 may 2026, 17:22 UTC

Charlas de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 may 2026, 16:57 UTC

Adquisiciones, fusiones, absorciones

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 may 2026, 16:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

18 may 2026, 16:57 UTC

Charlas de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 may 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Vinci Doesn't Set Out Financial Details of Deal

18 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 may 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Vinci Buys Canada's Modern Group of Companies

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

20.55% repunte

Estimación a 12 Meses

Media 35.31 USD 20.55%

Máximo 41 USD

Mínimo 29.5 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Roivant Sciences Ltd Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

298 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.